Chapter 1

Chapter 2

Chapter 3

Chapter 4

Chapter 5

Chapter 6 Drug Coverage

Hypertrophic Cardiomyopathy (HCM)

Vaccines: 2023 Year in Review

Eyecare

Urothelial Carcinoma

Women's Health

Depression

Hemophilia

Heart Failure

Vaccines

Neonatal Care

NSCLC

Type II Inflammation

Substance Use Disorder

Gene Therapy

Lung Cancer

Spinal Muscular Atrophy

Post-Acute Care

Liver Disease

Pulmonary Arterial Hypertension

Friedreich Ataxia

Safety & Recalls

Biologics

Asthma

Atrial Fibrillation

Skin Cancer

Type I Diabetes

Graft Versus Host Disease

COVID-19

Cardiovascular Diseases

Pain

Breast Cancer

Prescription Digital Therapeutics

Reproductive Health

The Improving Patient Access Podcast

Blood Cancer

Ulcerative Colitis

Respiratory Conditions

PTSD

Multiple Sclerosis

Digital Health

Population Health

Sleep Disorders

Biosimilars

Plaque Psoriasis

Leukemia and Lymphoma

Oncology

Pediatrics

Urology

Obstetrics-Gynecology & Women's Health

Opioids

Solid Tumors

Autoimmune Diseases

Dermatology

Diabetes

Mental Health

News

Media

Between the Lines

Expert Interviews

K-Cast

Medical World News

Podcasts

Population Health Perspectives

Conferences

Partners

Publications

All Publications

MHE Publication

Formulary Watch Supplements

Formulary Watch Spotlights

Supplements And Featured Publications

Events

2024 PBMI Annual National Conference

PBMI MAP

Virtual Events

CME/CE

Resources

Emerging Leaders

Interactive Tools

PBM Leaders

Subscribe

Articles

Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.

FDA Approves Biliary Tract Cancer Antibody Treatment 

Peter Wehrwein has been the lead editor of Managed Healthcare Executive since February 2020.

Kennedy's vaccines may give some Republican senators pause while Oz has an ally in Medicare Advantage plans. 

RFK Jr. and Oz, the Political Dynamics of the Trump Healthcare Duo

The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.

FDA Approves Bimzelx for Inflammatory Skin Disease

Featured in this latest episode of Tuning In to the C-Suite podcast is Paul Fronstin, director of health benefits research at EBRI, who shed light on the evolving landscape of health benefits with editors of Managed Healthcare Executive.

Breaking Down Health Plans, HSAs, AI With Paul Fronstin of EBRI

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, insights, and strategies to pursue value-driven solutions.

About Us

Advertise

Editorial

Contact Us

Terms and Conditions

Privacy

Do Not Sell My Personal Information

Managed Healthcare Executive

Facebook

LinkedIn

Resource Centers

Eye Care

Spotlight

ID Week 2024

AMCP Nexus 2024

AHIP

AIDS Conference

ATS 

Business

Business Strategy

Chronic Disease

Consumers

Drug Costs

Drug Pipeline

Formulary

Health Management

Health/Disease Strategy

Hospitals & Providers

Industry Analysis

Pharmacy

Politics and Policy

Practice Management

Reimbursement

Technology

Should “On-Demand” Treatments for Parkinson's disease OFF episodes be used earlier?

Meet the Speakers

PROGRAM OBJECTIVES

In this live broadcast, the experts will: